BICILLIN (penicillin g benzathine) by Thayer Medical is mechanism of action penicillin g exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. Approved for the treatment of infections due to penicillin-g-sensitive microorganisms, very prolonged serum levels common to this particular dosage form. First approved in 1951.
Drug data last refreshed 20h ago · AI intelligence enriched 1w ago
BICILLIN is penicillin G benzathine oral suspension approved in 1951 for treatment of penicillin-G-sensitive microbial infections. The drug exerts bactericidal action by inhibiting cell-wall peptidoglycan biosynthesis, rendering bacterial cell walls osmotically unstable. It is characterized by very prolonged serum levels unique to this benzathine formulation.
This legacy oral penicillin faces imminent loss of exclusivity with moderate competitive pressure (30), signaling a contracting team focused on defensive positioning and market maintenance rather than growth initiatives.
Mechanism of Action Penicillin G exerts a bactericidal action against penicillin-susceptible microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall peptidoglycan, rendering the cell wall osmotically unstable.
Worked on BICILLIN at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Azithromycin/Bicillin Syphilis
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BICILLIN offers limited career growth opportunity given its LOE-approaching status and zero linked job postings. Roles focus on defending market share, managing generic transition, and optimizing cost structures rather than innovation or expansion.